<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01945788</url>
  </required_header>
  <id_info>
    <org_study_id>1301</org_study_id>
    <nct_id>NCT01945788</nct_id>
  </id_info>
  <brief_title>Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo</brief_title>
  <official_title>Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio Sidus SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bio Sidus SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare efficacy and safety of two formulations of&#xD;
      teriparatide 20 mcg/day plus calcium and vitamin D in postmenopausal women with osteoporosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Bone mineral Density at 6 months.</measure>
    <time_frame>Basal, Six months and One Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in P1NP, Osteocalcin, C-terminal cross-linked telopeptide of type I collagen levels at 3 and 6 months</measure>
    <time_frame>Basal, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline on bone mineral density asessed by High-resolution peripheral quantitative computed tomography (HR-pQCT) at 6 months</measure>
    <time_frame>Basal, six months and one year.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with elevated serum calcium</measure>
    <time_frame>Basal, 1, 3, 6 and 12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Postmenopausal Osteoporosis With Pathological Fracture</condition>
  <arm_group>
    <arm_group_label>Teriparatide Forteo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 micrograms/day plus calcium and vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriparatide Osteofortil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 micrograms/day plus calcium and vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide (rDNA origin)</intervention_name>
    <arm_group_label>Teriparatide Forteo</arm_group_label>
    <arm_group_label>Teriparatide Osteofortil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        I. Female.&#xD;
&#xD;
        II. Age greater than or equal to 50 and less than 81 years.&#xD;
&#xD;
        III. Last menstrual period at least one year prior to signing the informed consent.&#xD;
&#xD;
        IV. Osteoporosis. Defined by the presence of:&#xD;
&#xD;
        BMD by DEXA with a T-score of -2.5 or lower on lumbar spine or T-score at the lumbar spine,&#xD;
        femoral neck or total hip -2.0 or below, together with one or more vertebral fractures&#xD;
        documented by lateral spine radiographs.&#xD;
&#xD;
        V. Have signed the informed consent&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        I Bone alkaline phosphatase in the blood above the normal limit without any explanation.&#xD;
&#xD;
        II. Liver disease (AST or ALT&gt; 2 x ULN). III. Renal disease (serum creatinine&gt; 2.0 mg / dl)&#xD;
        and / or creatinine clearance &lt;30 ml / min IV. Hypercalcemia ([Ca]&gt; 10.5 mg / dL). Patients&#xD;
        with elevated PTH in the presence of albumin-corrected calcium within normal values can be&#xD;
        re-evaluated.&#xD;
&#xD;
        V. Elevated blood PTH ([PTH]&gt; 65 pg / ml) Patients with elevated PTH in the presence of&#xD;
        albumin-corrected calcium within normal values can be re-evaluated.&#xD;
&#xD;
        VI. • Deficiency of vitamin D (25-OH vitamin D &lt;16 ng / ml) or excess vitamin D (above 80&#xD;
        ng / ml blood). Patients who did not meet the inclusion criteria for vitamin D may receive&#xD;
        a supplement (vitamin D) and be re-evaluated.&#xD;
&#xD;
        VII. • Anemia (hematocrit &lt;32%).&#xD;
&#xD;
        VIII. • History of cancer (except basal cell carcinoma) or radiotherapy.&#xD;
&#xD;
        IX. Severe cardiopulmonary disease, including coronary heart disease: unstable angina,&#xD;
        heart failure class III or IV or any other condition that the investigator believes may&#xD;
        prevent participation safely and complete the protocol procedures.&#xD;
&#xD;
        X. Major psychiatric disease that in the opinion of the investigator, would prevent to give&#xD;
        properinformed consent or complete the study procedures.&#xD;
&#xD;
        XI. Excessive alcohol or substance abuse that in the opinion of the investigator prevents&#xD;
        giving informed consent or complete proper protocol procedures.&#xD;
&#xD;
        XII. Congenital or acquired bone disease, other than osteoporosis (including osteomalacia,&#xD;
        hyperparathyroidism or Paget's disease)&#xD;
&#xD;
        XIII. Regarding the history of ingestion of oral bisphosphonates: After assessment of&#xD;
        adequate adherence (compliance greater than 75%), if the patient received six months of&#xD;
        treatment, she should have a bisphosphonate-free period of six months. If she took more&#xD;
        than six months, the bisphosphonate-free period must be 12 months.&#xD;
&#xD;
        XIV. Current or within the last 3 months before study entry estrogen use, selective&#xD;
        estrogen receptor modulators use or calcitonin use in therapeutic doses.&#xD;
&#xD;
        XV. Current use of systemic corticosteroids (oral or parenteral) for more than 14 days in&#xD;
        the last 6 months. Vaginal estrogen and isoflavones are permitted .&#xD;
&#xD;
        XVI.Current or previous use of teriparatide, other PTH analogues as patches or injectables,&#xD;
        strontium, fluorine or any intravenous bisphosphonate therapeutic dose, XVII. Known&#xD;
        hypersensitivity to pharmaceuticals derived from bacterial cells. XVIII. Hypersensitivity&#xD;
        to teriparatide or to any of its excipients. XIX.Nephrolithiasis or urolithiasis in&#xD;
        activity, according to the investigator opinion in the 5 years prior to randomization.&#xD;
&#xD;
        XX.Inflammatory bowel disease, malabsorption syndrome or any sign of intestinal calcium&#xD;
        malabsorption&#xD;
&#xD;
        XXI. Treatment with androgens or anabolic steroids in the 6 months prior to randomization.&#xD;
&#xD;
        XXII. Any medical condition that in the investigator opinion would contraindicate treatment&#xD;
        with an investigational drug.&#xD;
&#xD;
        XXIII. Treatment with coumarin and indandione derivatives in the 3 months prior to&#xD;
        randomization or treatment with heparins (at doses&gt; 10,000 U / day) for more than 30 days&#xD;
        in the 6 months prior to randomization.&#xD;
&#xD;
        XXIV.Treatment with any other drug known to affect bone metabolism, in therapeutic doses,in&#xD;
        the 6 months prior to randomization.&#xD;
&#xD;
        XXV.Treatment with an investigational drug during the month prior to randomization. -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto de Investigaciones Metabolicas</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>September 11, 2013</study_first_submitted>
  <study_first_submitted_qc>September 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2013</study_first_posted>
  <last_update_submitted>January 21, 2014</last_update_submitted>
  <last_update_submitted_qc>January 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
    <mesh_term>Fractures, Spontaneous</mesh_term>
    <mesh_term>Osteoporotic Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

